Effect of galantamine on time to residential or nursing home admission

Effect of galantamine on time to residential or nursing home admission

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Feldman, H, Wilcock, G, Van Baelen, B, Kavanagh, S
Μορφή:	Journal article
Έκδοση:	2004

Παρόμοια τεκμήρια

The effects of galantamine treatment on caregiver time in Alzheimer's disease.
ανά: Sano, M, κ.ά.
Έκδοση: (2003)

Galantamine in Alzheimer's disease.
ανά: Razay, G, κ.ά.
Έκδοση: (2008)

The beneficial effects of galantamine on caregiver time in Alzheimer's disease
ανά: Sano, M, κ.ά.
Έκδοση: (2003)

Safety and efficacy of galantamine in subjects with mild cognitive impairment.
ανά: Winblad, B, κ.ά.
Έκδοση: (2008)

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
ανά: Wilcock, G, κ.ά.
Έκδοση: (2000)

Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis.
ανά: Joffres, C, κ.ά.
Έκδοση: (2003)

Placement of dementia sufferers in residential and nursing home care.
ανά: Bannister, C, κ.ά.
Έκδοση: (1998)

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.
ανά: Wilcock, G, κ.ά.
Έκδοση: (2003)

Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial.
ανά: Pirttilä, T, κ.ά.
Έκδοση: (2004)

Three-year follow-up of galantamine therapy for Alzheimer's disease: Efficacy and tolerability in open-label extension studies
ανά: Wilcock, G, κ.ά.
Έκδοση: (2002)

A long-term comparison of galantamine and donepezil in the treatment of moderate-to-severe Alzheimer's disease: An intent-to-treat analysis
ανά: Wilcock, G, κ.ά.
Έκδοση: (2003)

Medical Conditions of Nursing Home Admissions
ανά: Nawrot Tim, κ.ά.
Έκδοση: (2010-07-01)

Long-term safety, tolerability and efficacy of galantamine: Results from a 36-month analysis of extension study data
ανά: Wilcock, G, κ.ά.
Έκδοση: (2002)

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial (vol 321, pg 1445, 2000)
ανά: Wilcock, G
Έκδοση: (2001)

Galantamine ameliorates experimental pancreatitis
ανά: Dane A. Thompson, κ.ά.
Έκδοση: (2023-10-01)

Galantamine vs donepezil in the treatment of Alzheimer's disease.
ανά: Goldlist, B, κ.ά.
Έκδοση: (2003)

Protective Effect of Galantamine against Doxorubicin-Induced Neurotoxicity
ανά: Rawan S. Alsikhan, κ.ά.
Έκδοση: (2023-06-01)

Home admission in COVID times: challenge for the actions of the nursing professional
ανά: Dayamí Guerra Villalpanda
Έκδοση: (2022-05-01)

Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9) (1445-1449))
ανά: Wilcock, G
Έκδοση: (2001)

Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9)(1445-1449))
ανά: Wilcock, G
Έκδοση: (2001)

Correction: Galantamine ameliorates experimental pancreatitis
ανά: Dane A. Thompson, κ.ά.
Έκδοση: (2024-04-01)

Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine
ανά: Yukio Ago, κ.ά.
Έκδοση: (2011-01-01)

QT interval prolongation and with donepezil, rivastigmine and galantamine
ανά: Katie Malone, κ.ά.
Έκδοση: (2020-08-01)

Het effect van galantamine op de ecg- geleidingstijden
ανά: I. C. Jobse, κ.ά.
Έκδοση: (2014-09-01)

Galantamine-memantine combination effective in dementia: Translate to dementia praecox?
ανά: Maju Mathew Koola, κ.ά.
Έκδοση: (2018-06-01)

Ameliorative effect of galantamine on acetic acid-induced colitis in rats
ανά: Niloofar-Sadat Mahdavi, κ.ά.
Έκδοση: (2019-01-01)

Galantamine-Memantine Combination in the Treatment of Parkinson’s Disease Dementia
ανά: Emma D. Frost, κ.ά.
Έκδοση: (2024-11-01)

Criteria for assessing a client's fitness for admission to a welfare home: a practical proposition.
ανά: Wilcock, G, κ.ά.
Έκδοση: (1982)

Changes in electrophysiological markers of cognitive control after administration of galantamine
ανά: Lauren E. Gascoyne, κ.ά.
Έκδοση: (2018-01-01)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
ανά: Yi-Ting Lin, κ.ά.
Έκδοση: (2019-05-01)

Synergistic Effects of Galantamine and Memantine in Attenuating Scopolamine-Induced Amnesia in Mice
ανά: Perrine Busquet, κ.ά.
Έκδοση: (2012-01-01)

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
ανά: E Loveman, κ.ά.
Έκδοση: (2006-01-01)

The Effect of Galantamine on Liver Function in Hepatic Ischemia/Reperfusion Injury in Rats
ανά: Majid Askaripour, κ.ά.
Έκδοση: (2019-06-01)

Effect of Donepezil, Tacrine, Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia tigrina
ανά: Cristiane Bezerra da Silva, κ.ά.
Έκδοση: (2016-01-01)

Hospital Admissions from Nursing Homes: Rates and Reasons
ανά: Kjell Krüger, κ.ά.
Έκδοση: (2011-01-01)

Fractures after nursing home admission: incidence and potential consequences.
ανά: Rapp, K, κ.ά.
Έκδοση: (2009)

Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study)
ανά: Paulo Caramelli, κ.ά.
Έκδοση: (2014-06-01)

Antidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting Drug.
ανά: Mennatallah A Ali, κ.ά.
Έκδοση: (2015-01-01)

Validation of a method for identifying nursing home admissions using administrative claims
ανά: Hsu Van Doren, κ.ά.
Έκδοση: (2007-12-01)

Are residential and nursing homes adequately screening overseas healthcare workers?
ανά: Loveday Rachel, κ.ά.
Έκδοση: (2008-08-01)